Tumoral angiogenesis: Review of the literature

Cancer Investigation

Volumn 26, Issue 1, 2008, Pages 104-108

  Shahi, Parham Khosravi ^a   Pineda, Israel Fernández ^b  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Angiogenesis; Bevacizumab; EGFR; Metronomic chemotherapy; VEGF

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER METRONOMIC CHEMOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; COLORECTAL CANCER; DRUG FATALITY; DRUG MECHANISM; ENDOTHELIUM CELL; GASTROINTESTINAL STROMAL TUMOR; GLIOMA; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MITOSIS; NEUROBLASTOMA; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; RECEPTOR BINDING; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 37849050760     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701662509     Document Type: Review

References (31)

1. Kerbel, R.S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006, 312, 1171-5.
2. Khosravi, P. Angiogenesis y neoplasias. Ann. Med. Interna. 2006, 23, 355-6.
3. Risau, W. Mechanisms of angiogenesis. Nature 1997, 386 (6626), 671-4.
4. Ferrara, N.; Gerber, H.P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 2003, 9 (6), 669-76.
5. Veikkola, T.; Karkkainen, M.; Claesson-Welsh, L.; et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000, 60 (2), 203-12.
6. Shim, W.S.; Ho, I.A.; Wong, P.E. Angiopoietin A TIE(d) Balance in Tumor Angiogenesis. Mol. Cancer Res. 2007, 5 (7), 655-65.
7. Kumar, R.; Yoneda, J.; Bucana, C.D.; et al. Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int. J. Oncol. 1998, 12 (4), 749-57.
8. Pugh, C.W.; Ratcliffe, P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 2003, 90 (6), 677-84.
9. Harris, AL. Hypoxia - a key regulatory factor in tumor growth. Nat. Rev. Cancer 2002, 2 (1), 38-47.
10. Folkman, J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 2007, 6 (4), 273-86.
11. Takahashi, Y.; Tucker, S.L.; Kitadai, Y.; et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch. Surg. 1997, 132 (7), 541-6.
12. Willett, C.G.; Boucher, Y.; di Tomaso, E.; et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 2004, 10 (2), 145-7.
13. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N. Engl. J. Med. 2004, 350 (23), 2335-42.
14. Sandler, A.; Gray, R.; Perry, M.C.; et al. Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2006, 355 (24), 2542-50.
15. Segerstrom, L.; Fuchs, D.; Bäckman, U.; Holmquist, K.; Christofferson, R.; Azarbayjani, F. The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts. Pediatr. Res. 2006, 60 (5), 576-81.
16. Abrams, T.J.; Lee, L.B.; Murray, L.J.; et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2003, 2 (5), 471-8.
17. Mendel, D.B.; Laird, A.D.; Xin, X.; et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003, 9 (1), 327-37.
18. O'Farrell, A.M.; Abrams, T.J.; Yuen, H.A.; et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101 (9), 3597-605.
19. Iliopoulos, O.; Levy, A.P.; Jiang, C. ; et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. U S A 1996, 93(20), 10595-9.
20. Maxwell, P.H.; Wiesener, M.S.; Chang, G.W.; et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399 (6733), 271-5.
21. Na, X.; Wu, G.; Ryan, C.K.; et al. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J. Urol. 2003, 170 (2), 588-92.
22. Motzer, R.J.; Hutson, T.E.; Tomczak, P.; et al. Sunitinib versus Interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007, 356 (2), 115-24.
23. Lyons, J.F.; Wilhelm, S.; Hibner, B.; Bollag, G. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer 2001, 8 (3), 219-25.
24. Ratain, M.J.; Eisen, T.; Stadler, W.M.; et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006, 24 (16), 2505-12.
25. Escudier, B.; Eisen, T.; Stadler, W.M.; et al. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. N. Engl. J. Med. 2007, 356 (2), 125-34.
26. Rini, B.; Rixe, O.; Bukowski, R.; et al.AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Proc. Am. Soc. Clin. Oncol. 2005, 4509 (Abstr).
27. Drevs, J.; Muller-Driver, R.; Wittig, C.; et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 2002, 62 (14), 4015-22.
28. Laquente, B.; Vinals, F.; Germa, J.R. Metronomic chemotherapy: an antiangiogenic scheduling. Clin. Transl. Oncol. 2007, 9 (2), 93-8.
29. Gasparini, G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol. 2001, 2 (12), 733-40.
30. Orlando, L.; Cardillo, A.; Rocca, A.; et al. Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer. Drugs 2006, 17 (8), 961-7.
31. Orlando, L.; Cardillo, A.; Ghisini, R.; et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patioents with Her-2 positive metastatic breast cancer. BMC Cancer 2006, 6 (5), 225-33.